H.C. Wainwright raised the firm’s price target on Nektar (NKTR) to $120 from $6.50 and keeps a Buy rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTR:
- Why Is Nektar Therapeutics Stock (NKTR) Up 110% Today?
- Nektar jumps 130% to $21.90 after atopic dermatitis study success
- Nektar Therapeutics Announces Positive Phase 2b Trial Results
- Nektar’s rezpegaldesleukin meets endpoints in Phase 2b atopic dermatitis trial
- Closing Bell Movers: Futures up on Iran/Israel truce, KB Home slips on outlook